MedTrace Logo

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

NCT04368039 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-02-25

No results posted yet for this study

Summary

Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.

Conditions

Interventions

DEVICE

Normobaric Oxygen

40% FiO2 for 4 weeks

DEVICE

Placebo

21% FiO2 for 4 weeks

Sponsors & Collaborators

  • Nicholas Breitborde

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-04
Primary Completion
2026-12-07
Completion
2026-12-07
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04368039 on ClinicalTrials.gov